Across TCGA pan-cancer cohorts, AKR1C1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of AKR1C1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where AKR1C1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types AKR1C1 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

LSCC, CCRCC, and COAD are the cancer types where AKR1C1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKR1C1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	II,III,IV	+1.140	<.001	7	view →
CCRCC	Male	All	−0.502	<.001	7	view →
COAD	Female	All	−0.538	.041	3	view →
LUAD	Female	III,IV	−0.813	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AKR1C1 RNA expression & survival · all AKR1C1 data types